Skip to content

Clinical trials

Diabetes Mellitus trials in China

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Diabetes Mellitus Country / region: China Clear all

411 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20023
20032
20043
20053
20065
20079
200814
200915
201016
201120
201215
201315
201411
201514
201619
201721
201815
201917
202011
202121
202233
202329
202439
202543
202617

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed194
Unknown status116
Recruiting47
Not yet recruiting20
Active, not recruiting15
Terminated10
Enrolling by invitation5
Withdrawn3
Suspended1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Novo Nordisk A/S45
Shanghai Jiao Tong University School of Medicine10
Chinese University of Hong Kong9
Shanghai Zhongshan Hospital9
Sun Yat-sen University8
Eli Lilly and Company7
Jiangsu HengRui Medicine Co., Ltd.7
Nanjing First Hospital, Nanjing Medical University7
Peking Union Medical College Hospital7
Peking University Third Hospital7

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Diabetes Mellitus411
Diabetes Mellitus, Type 2107
Hypertension34
Cardiovascular Diseases20
Diabetes Mellitus, Type 119
Obesity19
Insulin Resistance18
Metabolic Diseases15
Renal Insufficiency, Chronic15
Coronary Artery Disease14

Trials

Showing 76 to 100 of 411. Each trial links to its page on Pharma Observatory.

311 more trials match. See them on Pharma Observatory

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.